Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives $612.42 Consensus Target Price from Analysts

Posted by Brian Himes on Sep 24th, 2026

Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Free Report) have earned an average recommendation of “Moderate Buy” from the twenty brokerages that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, fifteen have given a buy rating and three have given a strong buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $612.4211.

PRAX has been the subject of several research reports. Wells Fargo & Company restated a “positive” rating and set a $362.00 price objective (up from $323.00) on shares of Praxis Precision Medicines in a research note on Friday, August 7th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $462.00 price objective (up from $449.00) on shares of Praxis Precision Medicines in a research note on Friday, August 7th. Truist Financial set a $616.00 target price on shares of Praxis Precision Medicines and gave the stock a “buy” rating in a report on Tuesday, June 2nd. Needham & Company LLC boosted their target price on shares of Praxis Precision Medicines from $575.00 to $582.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Praxis Precision Medicines in a report on Monday, July 13th.

View Our Latest Research Report on Praxis Precision Medicines

Praxis Precision Medicines Trading Down 6.2%

Shares of NASDAQ:PRAX opened at $282.12 on Monday. The company has a market cap of $7.88 billion, a price-to-earnings ratio of -21.82 and a beta of 2.76. The company has a 50-day moving average price of $337.62 and a 200-day moving average price of $322.08. Praxis Precision Medicines has a 12 month low of $46.99 and a 12 month high of $392.70.

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($2.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.67) by $0.80. As a group, research analysts forecast that Praxis Precision Medicines will post -13.92 EPS for the current fiscal year.

Institutional Trading of Praxis Precision Medicines

A number of hedge funds have recently modified their holdings of PRAX. Integrated Wealth Concepts LLC purchased a new position in shares of Praxis Precision Medicines during the 2nd quarter worth $38,000. Nykredit A S acquired a new position in Praxis Precision Medicines in the second quarter valued at about $261,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Praxis Precision Medicines during the second quarter worth about $2,698,000. Readystate Asset Management LP acquired a new stake in shares of Praxis Precision Medicines during the second quarter valued at about $3,531,000. Finally, Seven Fleet Capital Management LP purchased a new stake in shares of Praxis Precision Medicines in the 2nd quarter valued at approximately $2,524,000. Hedge funds and other institutional investors own 67.84% of the company’s stock.

Praxis Precision Medicines Company Profile

(Get Free Report)

Praxis Precision Medicines, Inc (NASDAQ: PRAX) is a biotechnology company focused on developing treatments for central nervous system disorders, including epilepsy, movement disorders and other neurological conditions. The company uses its Precision Genetic Medicine platform, which combines human genetics, functional genomics and neuroscience research to identify disease mechanisms and potential therapeutic targets.

Praxis’ pipeline has included investigational medicines such as ulixacaltamide, a treatment candidate being developed for essential tremor, and elsunersen, an antisense oligonucleotide designed for certain severe genetic epilepsies.